Integrity Alliance LLC. Purchases 9,234 Shares of Eli Lilly and Company $LLY

Key Points

• Integrity Alliance LLC increased its stake in Eli Lilly and Company by 860.6%, acquiring an additional 9,234 shares, bringing its total holdings to 10,307 shares valued at approximately $8.5 million.
• Eli Lilly reported a 37.6% year-over-year increase in quarterly revenue, reaching $15.56 billion, and earnings per share of $6.31, exceeding estimates by $0.72.
• The company declared a quarterly dividend of $1.50 per share, scheduled for payment on September 10th, with a total dividend payout ratio of 39.22%.

Integrity Alliance LLC. increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 860.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,307 shares of the company's stock after acquiring an additional 9,234 shares during the quarter. Integrity Alliance LLC.'s holdings in Eli Lilly and Company were worth $8,512,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Redwood Investments LLC lifted its position in Eli Lilly and Company by 0.5% during the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock worth $1,705,000 after buying an additional 12 shares in the last quarter. Hobbs Wealth Management LLC lifted its position in Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after purchasing an additional 12 shares during the period. Hixon Zuercher LLC lifted its position in Eli Lilly and Company by 0.7% during the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after purchasing an additional 12 shares during the period. O Brien Wealth Partners LLC lifted its position in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the period. Finally, Ascent Capital Management LLC lifted its position in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the period. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jamere Jackson bought 200 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock worth $2,894,841 in the last quarter. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $749.99 on Wednesday. The company has a market capitalization of $709.84 billion, a price-to-earnings ratio of 49.02, a P/E/G ratio of 1.03 and a beta of 0.47. The firm's 50 day simple moving average is $742.49 and its 200 day simple moving average is $779.42. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $942.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same period last year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research reports. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. UBS Group cut their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.